GlassScriptPhysician profile
Duri Yun
NPI 1790934297
$1,034.13
in general payments reported to CMS, 2019-2025
12 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.38 · 2022: $58.78 · 2023: $156 · 2024: $361 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $344.70 | 2024-2025 | |
| Pfizer INC. | $240.36 | 2023-2025 | |
| Abbvie INC. | $127.52 | 2019-2023 | Rinvoq |
| Pierre Fabre Pharmaceuticals, INC. | $75.94 | 2025 | Hemangeol |
| Incyte Corporation | $49.55 | 2023-2024 | Opzelura |
| Nobelpharma America, LLC | $44.98 | 2024 | |
| Arcutis Biotherapeutics, INC. | $41.43 | 2023 | |
| Amgen INC. | $29.22 | 2024 | Otezla |
| Organon LLC | $25.12 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $22.97 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $17.08 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.26 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duri Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.